China evaluating investigations into pharma firms to take on drug pricing issue
pharmafile | May 9, 2016 | News story | Business Services, Research and Development, Sales and Marketing |Â Â China, France, G7, regulationÂ
Lawmakers globally have acknowledged the concerns over unbridled drug costs as regulators stress the need for a more open debate with the pharma industry.
Joining the pack is China, where the regulators are reportedly set to launch anti-trust investigations against pharma firms. The reports suggest the government plans a large-scale and systematic scrutiny into drugmakers both foreign and domestic.
The National Development and Reform Commission is gathering proof to establish if these pharma firms were in violation of guidelines pertaining to competition.
The news come close on the heels of reports France is looking at proposing joint action against drug pricing at the upcoming G7 meet.
Bottom-lines for drugmakers have taken a hit since China took to making its public healthcare system affordable.
Anjali Shukla
Related Content

CARBOGEN AMCIS manufacturing license advances services in China
Swiss pharma manufacturing company, CARBOGEN AMCIS, has announced that its facility in Shanghai, China, has …

NDA in China receives priority review status for lung cancer treatment
HUTCHMED have announced that the China National Medical Products Administration (NMPA) have granted a priority …

China’s NMPA accepts Everest Medicines’ Nefecon supplementary application
Everest Medicines has announced that China’s National Medical Products Administration (NMPA) has accepted the submission …






